Unknown

Dataset Information

0

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.


ABSTRACT: Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group (hazard ratio, 0.68; P ? 0.003). Serious (grade 3-5) immune-related adverse events occurred in 10% to 15% of patients. Thus, although it provides a clear survival benefit, ipilimumab administration requires careful patient monitoring and sometimes necessitates treatment with immune-suppressive therapy. Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma.

SUBMITTER: Lipson EJ 

PROVIDER: S-EPMC3575079 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.

Lipson Evan J EJ   Drake Charles G CG  

Clinical cancer research : an official journal of the American Association for Cancer Research 20110907 22


Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overal  ...[more]

Similar Datasets

| S-EPMC4963052 | biostudies-literature
| S-EPMC3544906 | biostudies-literature
| S-EPMC8007150 | biostudies-literature
| S-EPMC5935561 | biostudies-literature
| S-EPMC5991705 | biostudies-literature
| S-EPMC4306338 | biostudies-literature
| S-EPMC3549297 | biostudies-literature
| S-EPMC6027578 | biostudies-literature
| S-EPMC5993498 | biostudies-literature
| S-EPMC6020711 | biostudies-literature